Lainie P. Martin - Concepedia

Author

Lainie P. Martin

Also Known As

C Richart, L Martin, L Martín, L P Martin, L. Martin, L. P. Martin, L.P. Martin, Lainie Martin, Lainie P Martin, Lainie P. Martin

276

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

Fox Chase Cancer Center Memorial Sloan Kettering Cancer Center University of Pennsylvania Massachusetts General Hospital The Ohio State University

About

Lainie P. Martin is an author at Fox Chase Cancer Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	37	3.4K
2	Public Health	4	4	381
3	Health Sciences	3	3	63
4	Epidemiology	1	1	60
5	Gastroenterology	1	1	79

Lainie P. Martin

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Journal of the National Comprehensive Cancer Network Surgical OncologyEpithelial Ovarian CancerCancer ManagementPelvic Reconstructive SurgeryGynecology	2021	688
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022 Deborah K. Armstrong, Ronald D. Alvarez, Floor Backes, Journal of the National Comprehensive Cancer Network Nccn Guidelines® InsightsTumoral PathologyEndocrine-related CancerEpithelial Ovarian CancerMedicine	2022	369
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer John K. Chan, Mark F. Brady, Richard T. Penson, New England Journal of Medicine	2016	355
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology Robert J. Morgan, Deborah K. Armstrong, Ronald D. Alvarez, Journal of the National Comprehensive Cancer Network Cancer ManagementGynecologyPathologyGynecology OncologyCarcinoma	2016	318
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, New England Journal of Medicine	2023	316
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study Kathleen N. Moore, Lainie P. Martin, David M. O’Malley, Journal of Clinical Oncology Cancer ManagementImmunologyPathologyFallopian TubeOvarian Cancer	2017	212
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Clinical Cancer Research	2017	203
Ovarian Cancer, Version 3.2012 Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Journal of the National Comprehensive Cancer Network	2012	196
Uterine Neoplasms, Version 1.2014 Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu‐Rustum, Journal of the National Comprehensive Cancer Network Uterine SarcomasEndometriosisPathologyGynecologyGynecology Oncology	2014	183
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma Stéphanie Lheureux, Marcus O. Butler, Blaise Clarke, JAMA Oncology	2017	159

Page 1